TB-500 vs Adrenomedullin

This comparison examines TB-500 and Adrenomedullin side by side, focusing on mechanism, evidence strength, and typical research contexts. TB-500 is used primarily in preclinical models of injury recovery and inflammation, with limited human trial data. Adrenomedullin is extensively studied as a biomarker (MR-proADM) in sepsis and heart failure, and as a vasodepressor peptide in physiology research. Researchers should weigh the mature biomarker evidence for Adrenomedullin against the direct tissue-repair claims for TB-500, which remain largely outside approved therapeutic frameworks.

Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide expressed in most mammalian tissues. TB-500 is the synthetic fragment containing the actin-binding motif Ac-LKKTETQ (molecular weight ~889 g/mol), which promotes cell migration, wound healing, and tissue remodeling. It is administered as a standalone research agent to model Tβ4 activity. The evidence base includes a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults that reported minimal adverse effects. Despite this, TB-500 remains unapproved for therapeutic use in all major markets and is banned by WADA and in horse racing. Key claims—accelerating wound healing, reducing inflammation, and promoting cardiac repair—are supported mostly by animal models and small human studies, so the mechanistic rationale is stronger than the clinical validation.

Adrenomedullin is a 52-amino-acid vasodilatory peptide (molecular weight ~6028 g/mol) first isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, and exerts potent vasodilatory, natriuretic, and cardioprotective effects. In current research, the stable fragment MR-proADM is used as a prognostic biomarker in sepsis and acute heart failure, rather than as a therapeutic agent. Key claims center on its predictive value: MR-proADM is strongly associated with sepsis severity and mortality, and independently predicts adverse outcomes in acute heart failure. The peptide itself also produces clear vasodilation in human infusion studies. The evidence base is mature for biomarker research, but there is no approved therapeutic use, and the peptide's short half-life and hemodynamic potency complicate its experimental administration.

The research applications diverge sharply. TB-500 is investigated primarily as a pro-repair agent—studied in models of muscle/tendon injury, dermal wound healing, and inflammation—where the aim is to accelerate regeneration or recovery. Adrenomedullin is used in cardiovascular and critical care research, mainly as a biomarker for risk stratification in sepsis and heart failure, and as a physiologic tool for studying vasodilation and sodium handling. If the research question concerns tissue repair or inflammatory resolution, TB-500 is the relevant peptide. If the question involves prognostication, hemodynamic regulation, or biomarker validation in critically ill populations, Adrenomedullin—specifically MR-proADM—is the appropriate choice. The overlap in practical applications is minimal, making the decision largely context-driven.

TB-500 has the more favorable published safety profile for an investigational peptide. A safety-focused RCT in 40 healthy adults found minimal adverse effects with synthetic thymosin beta-4, and published human studies to date report no significant safety concerns. Anecdotal side effects commonly noted include injection site pain and redness, lightheadedness, mild headache, nausea, and fatigue. In contrast, Adrenomedullin lacks controlled therapeutic safety data in humans. Experimental IV infusion in healthy volunteers causes hypotension and reflex tachycardia, and there is a theoretical risk of excessive vasodilation leading to hemodynamic instability. For researchers choosing between the two, TB-500's risks appear limited to minor transient effects, while Adrenomedullin requires careful hemodynamic monitoring and is rarely administered as an investigational therapeutic.